Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.
about
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsDifferences between ceftriaxone and cefotaxime: microbiological inconsistenciesCampylobacter and fluoroquinolones: a bias data set?Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiEvaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationThe evolution of the regulatory framework for antibacterial agentsWorldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study TeamPharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.Setting and revising antibacterial susceptibility breakpoints.Antimicrobial drug resistance, regulation, and research.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists.Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.Pharmacological considerations for the proper clinical use of aminoglycosides.Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.AZDAST the new horizon in antimicrobial synergism detection.Specific antibiotics in the treatment of periodontitis--a proposed strategy.The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.Rationale for the 2010 Revised Susceptibility Breakpoints for Cephalosporins, Aztreonam, and Carbapenems for Enterobacteriaceae.Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.Population pharmacokinetics of cefotaxime and dosage recommendations in children with sickle cell disease.Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection.
P2860
Q28066877-07732A76-8D80-4E0A-BB6F-53F7DEC14872Q28261698-6C785045-37E8-4D9E-9280-E6E18D97E640Q30781159-28714BB7-3290-4C25-A1E7-40A32958122CQ33769931-72B9B6DC-6939-4043-B09D-E4B46F1F591DQ34077003-AEA276C0-2B3A-42BA-A57F-55DF96CC3EAEQ34188814-5B5F41CB-7EED-4D03-A283-FA8812370799Q34693386-EB50EF65-37B0-4709-B201-01379C3892A0Q34725279-1248C658-C57F-4DFB-A0F9-67D66B8B8D6BQ34937147-105F5C9E-6FD2-4F8F-BA5D-53193A75B317Q35091285-8E54189E-03C3-4CF6-B3B6-C2D9C663E2CAQ35913176-8E1615B5-1E9D-4F30-89DF-5657E4ED5C4DQ36026412-C88F53BE-9C1D-4D79-8DD0-7BBCAD41ACDAQ36162355-81A7E1BD-0AEC-4E40-8973-FF13DE4B8AC9Q36408747-9BDE4B9C-1405-459A-94AC-F93170D5318AQ37115679-5FD00345-2A09-48CB-A6FE-A42AD789B012Q37661510-F680C2F4-FC8A-4B5E-BF03-51446EE40A8CQ37733667-B7604743-3202-4359-926F-11F00220B8B3Q37956403-4950E1EC-DF23-43A8-825D-3A50FEC763FCQ38075482-D28BA7C6-DD26-433F-945C-C4AF8E0C25DEQ38258649-B52878DB-A446-42D2-AFFA-06338C496F8FQ40369820-36525C88-0B04-410D-A8CB-46C7FA39D47BQ40922179-FF4895FB-8CF9-4A98-9433-683B1B191A54Q42465266-D056D556-FE35-4DA2-A112-371563EB0A0DQ44801874-EA2FF3A2-E165-4167-8FAB-7FC2C58E5DD6Q45170003-F34098C9-4177-419B-ACC6-B6DD16B76479Q45950135-ABF17E78-5257-48E9-B173-493E62BC77D9Q46255695-4B9BBB16-A05A-4AA8-8C86-731CD8755AE5Q49429759-D5A3C1DC-9FC2-4F3D-9F86-81744CF00EDAQ49598847-8ECCCD2D-73B8-48A7-88BC-8B099446BDA4Q55053522-8EE54A64-212B-4D68-BC09-181A28087502
P2860
Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@ast
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@en
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@nl
type
label
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@ast
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@en
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@nl
prefLabel
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@ast
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@en
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@nl
P1476
Pharmacodynamics in the study ...... kpoints: ready for prime time.
@en
P2093
P304
P356
10.1016/S1369-5274(00)00132-6
P577
2000-10-01T00:00:00Z